Want to see AORT full AI Analyst Report?
AORT Stock Chart & Stats
$25.28
$0.82(3.24%)
At close: 4:00 PM EDT
$25.28
$0.82(3.24%)
Day’s Range― - ―
52-Week Range$19.16 - $48.25
Previous Close$26.62
Volume427.60K
Average Volume (3M)724.70K
Market Cap
$1.34B
Enterprise Value$2.02K
Total Cash (Recent Filing)$55.76M
Total Debt (Recent Filing)$258.16M
Price to Earnings (P/E)107.7
Beta0.70
Next Earnings
Aug 06, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.25
Shares Outstanding48,543,350
10 Day Avg. Volume508,030
30 Day Avg. Volume724,698
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)4.61
Price to Sales (P/S)4.69
P/FCF Ratio-2.27K
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$42.67Price Target Upside68.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.08
Revenue Forecast (FY)$486.23M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & ProfitabilityConsistent multi-year revenue growth and a return to positive net income and operating margins (~6.8% TTM) indicate durable demand for core vascular and tissue products. This improves scale economics and supports sustainable reinvestment in R&D and commercial expansion over the next 2–6 months.
Improved Balance Sheet / DeleveragingMarked reduction in leverage and larger equity base give the company greater financial flexibility to fund launches, manage supply issues, and absorb integration costs. Lower leverage reduces refinancing risk and supports strategic investments and M&A execution in the medium term.
Strategic Aortic-Arch Portfolio ExpansionOwning NEXUS plus AMDS and C-Branch LSA creates a differentiated aortic-arch franchise with a broader addressable market and cross-sell potential. The deal and pipeline (ARTISON, C-Branch LSA) provide structural product catalysts that should support multi-year revenue diversification and competitive positioning.
Bears Say
Thin Net Margins & Volatile Free Cash FlowLow net margins and historically volatile free cash flow limit the company's ability to consistently fund growth initiatives, absorb shocks, or self-fund acquisitions. Even with recent improvement, inconsistent cash conversion raises dependence on external financing and constrains durable internal reinvestment.
Guidance Cut & AMDS Timing RiskDelayed AMDS starter-set purchases reflect adoption and administrative hurdles that can push expected revenue and conversion timing into later periods. Execution timing risk for a key growth driver undermines near-term visibility and could postpone durable improvements in procedure penetration.
Acquisition Financing And Near-Term Earnings PressureFinancing the Endospan deal raises interest expense and temporarily reduces adjusted EBITDA, constraining margin expansion and free cash flow. Integration and contingent earnouts add execution and payout risk, limiting near-term financial flexibility and increasing earnings volatility.
AORT FAQ
What was Artivion Inc.’s price range in the past 12 months?
Artivion Inc. lowest stock price was $19.16 and its highest was $48.25 in the past 12 months.
What is Artivion Inc.’s market cap?
Artivion Inc.’s market cap is $1.34B.
When is Artivion Inc.’s upcoming earnings report date?
Artivion Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 6 days.
How were Artivion Inc.’s earnings last quarter?
Artivion Inc. released its earnings results on May 07, 2026. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.026 by $0.004.
Is Artivion Inc. overvalued?
According to Wall Street analysts Artivion Inc.’s price is currently Undervalued.
Does Artivion Inc. pay dividends?
Artivion Inc. pays a Quarterly dividend of $0.03 which represents an annual dividend yield of N/A. See more information on Artivion Inc. dividends here
What is Artivion Inc.’s EPS estimate?
Artivion Inc.’s EPS estimate is <0.01.
How many shares outstanding does Artivion Inc. have?
Artivion Inc. has 48,543,350 shares outstanding.
What happened to Artivion Inc.’s price movement after its last earnings report?
Artivion Inc. reported an EPS of $0.03 in its last earnings report, beating expectations of $0.026. Following the earnings report the stock price went down -28.261%.
Which hedge fund is a major shareholder of Artivion Inc.?
Currently, no hedge funds are holding shares in AORT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artivion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.67 (68.78% Upside)
$42.67 (68.78% Upside)
Blogger Sentiment
Bullish
AORT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 598.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.63%
Trailing 12-Months
Company Description
Artivion Inc.
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
AORT Company Deck
AORT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally constructive long-term story—double-digit revenue growth, strong adjusted EBITDA expansion, margin improvement, encouraging product-level performance (notably On-X and tissue processing), rapid deleveraging, and a strategic acquisition (Endospan/NEXUS) that completes a differentiated aortic arch portfolio. Near-term execution challenges—lower-than-expected AMDS starter-set conversions, regional softness (Middle East), targeted supply-chain constraints, and a moderated full-year guidance—tempered the immediate outlook. Management provided clear remediation plans (value analysis committee work, programs to reduce the upfront AMDS burden, inventory and hiring plans for NEXUS) and maintained multi-year pipeline catalysts (ARTISON, C-Branch LSA) that support future upside.View all AORT earnings summariesAORT Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$42.67
▲(68.78% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
5.28% Insiders
33.45% Mutual Funds
3.44% Other Institutional Investors
36.61% Public Companies and
Individual Investors









